SEC Form 4 · accession 0001354488-16-006989
Cellular Biomedicine Group, Inc. · CBMG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wei (William) Cao
Director
Period of report
Mar 1, 2016
Accepted (ET)
Apr 14, 2016 · 11:08 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001378624
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2016 | M | 10,000 | $5.40 | A | 184,472 | D | |
| Common Stock | Mar 1, 2016 | S | 10,000 | $17.15 | D | 174,472 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non- Qualified Stock Option (right to buy) (2013 Plan)F3,F2 | $5.40 | Mar 1, 2016 | M | 10,000 | A | — | Sep 30, 2023 | Common Stock | 10,000 | 40,000 | D |
Explanation of responses
- F1The transaction reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2015. Accordingly, the reporting person had no discretion with regard to the timing of the transaction.
- F2The option vests according to the following schedule: 1/36th per month following the vesting commencement date of September 30, 2013.
- F3Due to a delay in communication with regard to the timing of the transactions reported herein, the total number of derivative securities of the issuer beneficially owned by the reporting person reported in his Form 4 filed on March 4, 2016 did not account for the change in derivative securities owned as a result of the transactions reported herein. As of the date of this report, the total number of derivative securities of the issuer beneficially owned by the reporting person under his 2013 non-qualified stock option plan is 32,500.